(Q36210864)

12 August 2017

1 reference

title

T cell-mediated immunotherapy of metastases: state of the art in 2005. (English)

1 reference

12 August 2017

1 reference

Volker Schirrmacher

1

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

Expert Opinion on Biological Therapy

12 August 2017

published in

1 reference

12 August 2017

volume

5

1 reference

12 August 2017

issue

8

1 reference

12 August 2017

page(s)

1051-1068

1 reference

Analysis of the B-cell repertoire against antigens expressed by human neoplasms

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Tumor antigens recognized by T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Progress in the development of immunotherapy for the treatment of patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Antigen localization and migration in immunity and tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

The three Es of cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Cancer immunotherapy: a treatment for the masses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

SYFPEITHI: database for MHC ligands and peptide motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic growth of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Technical and regulatory hurdles for DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Tumor vaccines: from gene therapy to dendritic cells--the emerging frontier

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

T cells take aim at cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Advances in immune-based therapies of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Tumour cell-dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylen-glycol versus electro-fusion protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Immunization with tumor-derived ER chaperone grp170 elicits tumor-specific CD8+ T-cell responses and reduces pulmonary metastatic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

A different pattern of cytotoxic T lymphocyte recognition against primary and metastatic tumor cells in a patient with nonsmall cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Increased activation-induced cell death in peripheral lymphocytes of rheumatoid arthritis patients: the mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

CpG motifs in bacterial DNA and their immune effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Does the immune system see tumors as foreign or self?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

A novel tumour model system for the study of long-term protective immunity and immune T cell memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Maintenance of long-term tumour-specific T-cell memory by residual dormant tumour cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Danger signals: SOS to the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Viral hemagglutinin augments peptide-specific cytotoxic T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Delivery technologies for human vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Alphavirus vectors and vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Stimulation of human natural interferon-alpha response via paramyxovirus hemagglutinin lectin-cell interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Effective anti-metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with Newcastle disease virus (NDV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

TNF autovaccination induces self anti-TNF antibodies and inhibits metastasis in a murine melanoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Conditional mouse models of sporadic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Response of naïve and memory CD8+ T cells to antigen stimulation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

T cell memory, anergy and immunotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Immunotherapy for lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Part I: Vaccines for solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

In vivo 1H-NMR microimaging with respiratory triggering for monitoring adoptive immunotherapy of metastatic mouse lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

T-cell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Roles of interferon-regulatory factors in T-helper-cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Persistence of dormant tumor cells in the bone marrow of tumor cell-vaccinated mice correlates with long-term immunological protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Bone marrow is a preferred site for homeostatic proliferation of memory CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Targeting Alloreactive Donor T-Cells to Hematopoietic System-Restricted Minor Histocompatibility Antigens to Dissect Graft-versus-Leukemia Effects from Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

New strategies for prevention and treatment of graft-versus-host disease and for induction of graft-versus-leukemia effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Adoptive-cell-transfer therapy for the treatment of patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

IL-7 and IL-15: therapeutic cytokines for immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Mini-review: overcoming tumor-intrinsic resistance to immune effector function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Cytokines and the regulation of hypoxia-inducible factor (HIF)-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Liver endothelial cells: participation in host response to lymphoma metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Superiority of the ear pinna over muscle tissue as site for DNA vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Superiority of the ear pinna over a subcutaneous tumour inoculation site for induction of a Th1-type cytokine response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

T-cell immunity in the induction and maintenance of a tumour dormant state

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.8.1051

10.1517/14712598.5.8.1051

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference